Case Overview

In a pharmaceutical patent dispute that concluded as swiftly as it began, American Regent, Inc. voluntarily dismissed its infringement action against Somerset Therapeutics, LLC and co-defendants Odin Pharmaceuticals, LLC and Somerset Pharma, LLC — just 42 days after filing. The case, docketed as 1:24-cv-00249 before the Delaware District Court, centered on U.S. Patent No. US11786548B2, covering a specialized trace elements injection formulation used in clinical nutrition therapy.

The dismissal without prejudice, filed pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i), raises immediate strategic questions: Did pre-litigation negotiations succeed? Did patent counsel identify a claim vulnerability early? Or does this represent a tactical repositioning ahead of future enforcement? For patent attorneys, IP professionals, and pharmaceutical R&D teams, the case offers instructive lessons on early-stage patent litigation strategy, voluntary dismissal mechanics, and the competitive dynamics surrounding specialty injectables — an increasingly contested pharmaceutical patent space.

The Parties

The Patent at Issue

The asserted patent, U.S. Patent No. US11786548B2 (Application No. US17/365695), covers a trace elements injection formulation. At its commercial core, the patent relates to a precisely compounded multi-mineral parenteral product containing:

• • Zinc: 1,000 mcg
• • Copper: 60 mcg
• • Manganese: 3 mcg
• • Selenium: 6 mcg
• • Delivered in single-dose 1 mL vials under the product designation Trace Elements Injection 4*, USP

This formulation serves patients requiring intravenous micronutrient supplementation, particularly in critical care and long-term parenteral nutrition settings.

The Accused Product

The defendants were alleged to infringe through their own version of the Trace Elements Injection 4* USP product — a formulation matching the precise elemental concentrations and delivery format protected under American Regent’s patent claims.

Legal Representation: American Regent was represented by attorney Christopher Viceconte of Gibbons PC, a well-regarded Mid-Atlantic law firm with established pharmaceutical and IP litigation capabilities. No defense counsel appeared on record prior to dismissal, consistent with the case’s extremely short lifecycle.

Litigation Timeline & Legal Analysis

Litigation Timeline & Procedural History

Venue: The Delaware District Court is the preeminent forum for pharmaceutical patent litigation, particularly for Hatch-Waxman and specialty drug disputes. Its experienced judiciary, established IP case management procedures, and proximity to major pharmaceutical corporate registrations make it a deliberate, strategic choice for plaintiffs like American Regent.

Presiding Judge: The Honorable Maryellen Noreika, Chief Judge of the Delaware District Court, was assigned to this matter. Judge Noreika has an extensive pharmaceutical and life sciences patent litigation docket, bringing significant subject-matter familiarity to complex drug formulation disputes.

The case closed before any substantive motions — including answers, preliminary injunction briefings, or claim construction proceedings — were entered on the record. This 42-day window from filing to voluntary dismissal is notably compressed, suggesting the resolution point — whatever it may have been — was reached during the pre-answer or early negotiation phase of the litigation.

Outcome

American Regent, Inc. filed a voluntary dismissal without prejudice on April 5, 2024, pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). This procedural mechanism allows a plaintiff to dismiss an action unilaterally before the opposing party serves an answer or a motion for summary judgment.

No damages were awarded. No injunctive relief was granted or denied. Because the dismissal was without prejudice, American Regent retains the legal right to refile the same infringement claims against the same defendants in the future, provided applicable statutes of limitations are observed.

Verdict Cause Analysis

The listed verdict cause is Infringement Action, confirming that patent infringement under 35 U.S.C. § 271 formed the basis of the original complaint. However, since no substantive rulings were issued — no claim construction order, no invalidity findings, no infringement determination — the legal record offers limited doctrinal output.

What the record *does* reveal is a strategic calculus. A Rule 41(a)(1)(A)(i) dismissal is available only before the defendant serves a responsive pleading. The defendants’ absence from the attorney record and the lack of any filed answer within the 42-day window is consistent with this timeline. Plaintiffs deploying this mechanism often do so for several reasons:

• Settlement or licensing resolution reached privately between the parties
• Claim strength reassessment following closer review of the defendants’ product specifications or prosecution history
• Commercial negotiation leverage — filing to signal enforcement intent, then withdrawing to formalize a business arrangement
• Reformulation or market withdrawal by the defendant rendering continued litigation unnecessary

Without prejudice dismissals in pharmaceutical patent cases frequently precede refiling — either in the same venue or before the International Trade Commission (ITC) — if the underlying commercial conflict remains unresolved.

Legal Significance

This case does not generate binding precedent; no substantive legal ruling was issued. However, it carries observational significance for several reasons:

1. Early enforcement signaling in trace elements and parenteral nutrition formulations demonstrates American Regent’s willingness to assert U.S. Patent No. US11786548B2 aggressively.
2. The involvement of three related defendant entities reflects the complex corporate structures generic pharmaceutical entrants deploy, and plaintiffs must ensure complete party joinder to avoid gaps in relief.
3. The without prejudice designation preserves optionality — a litigation-ready posture that keeps defendants on notice.